Sophia Genetics SA (NAS:SOPH)

$ 4.73 -0.01 (-0.21%) Market Cap: 309.22 Mil Enterprise Value: 222.93 Mil PE Ratio: 0 PB Ratio: 2.34 GF Score: 40/100

Q1 2024 Sophia Genetics SA Earnings Call Transcript
May 07, 2024

$4.97 (-1.58%)

Earnings
Q4 2023 Sophia Genetics SA Earnings Call Transcript
Mar 05, 2024

$5.6 (-0.36%)

Earnings
Q3 2023 Sophia Genetics SA Earnings Call Transcript
Nov 07, 2023

$3.91 (+1.30%)

Earnings
Q2 2023 Sophia Genetics SA Earnings Call Transcript
Aug 08, 2023

$3.55 (+5.65%)

Earnings
Q1 2023 Sophia Genetics SA Earnings Call Transcript
May 09, 2023

$4.85 (+1.89%)

Earnings
Sophia Genetics SA at Barclays Global Healthcare Conference Transcript
Mar 14, 2023
Full Year 2022 Sophia Genetics SA Earnings Call Transcript
Mar 07, 2023

$2.53 (-1.94%)

Earnings
Sophia Genetics SA at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Sophia Genetics SA Earnings Presentation Transcript
Nov 08, 2022
Sophia Genetics SA Investor Day 2022 Transcript
Sep 20, 2022
Q2 2022 Sophia Genetics SA Earnings Call Transcript
Aug 09, 2022

$4.79 (-6.08%)

Earnings
Q1 2022 Sophia Genetics SA Earnings Call Transcript
May 10, 2022

$4.91 (-10.56%)

Earnings
Sophia Genetics SA at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Full Year 2021 Sophia Genetics SA Earnings Call Transcript
Mar 15, 2022

$8.21 (-9.68%)

Earnings
Sophia Genetics SA at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Q2 2021 Sophia Genetics SA Earnings Call Transcript
Sep 09, 2021

$17.42 (-1.91%)

Earnings

Sophia Genetics SA at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 04:15PM GMT

Release Date Price: $2.56 (+14.29%)

Transcript

Marta Nazarovets

All right. Well, good morning, everyone. My name is Marta Nazarovets. I'm from the growth life science tools and diagnostics team. Welcome to the second day of JPMorgan Health Conference. It is my pleasure to introduce our next company, SOPHiA GENETICS. (Operator Instructions)

And with that, I will turn it over to Jurgi.

Jurgi Camblong

SOPHiA GENETICS SA - Co-Founder, CEO & Director

Thank you very much, Marta. Good morning, everyone. Pleasure being here. So I'm Jurgi Camblong, I'm the CEO of SOPHiA GENETICS. And today, I'm going to present you the SOPHiA story, and I'm going to elaborate our 2022 performance as well as what will be our 2023 focus areas.

So before I start, as usually, I may be presenting some forward-looking statements. So I want you to take notice of this cautionary notice.

So SOPHiA was founded in 2011 with the promise of creating a world of data-driven medicine, basically moving from hypothesis-driven medicine to data-driven medicine. And today, I'm pretty proud to say that we've been not too bad

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.